nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

for form 1449/PTO

Complete if Known 10/551,203 **Application Number** Filing Date June 29, 2006 First named Inventor Simon West 1612 Group Art Unit Snigdha Maewall Examiner name 024944-9015-US00 Attorney Docket Number

(use as many sheets as necessary) Sheet 1 of 9

U.S. Patent Documents

	U.S. Patent Documents					
Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document			
	2,407,823	Fieser	9/17/1946			
	2,913,477	Hirschmann	11/17/1959			
	3,212,901	Robeson	10/19/1965			
	4,075,333	Josse	2/21/1978			
	4,141,938	Klose	2/27/1979			
	4,299,906	Liu	11/10/1981			
	4,654,373	Bertelli	3/31/1987			
	4,684,520	Bertelli	8/4/1987			
,	4,686,211	Hara et al.	8/11/1987			
	4,874,883	Uphues et al.	10/17/1989			
	4,952,495	Belly et al.	8/28/1990			
	5,041,434	Lubkin	8/20/1991			
	5,053,222	Takasu et al.	10/1/1991			
	5,091,848	Kojima	2/25/1992			
	5,094,848	Brixner	3/10/1992			
	5,114,957	Hendler et al.	5/19/1992			
	5,138,084	Casagrande et al.	8/11/1992			
	5,173,304	Lohner et al.	12/22/1992			
	5,374,645	Kurihara-Bergstrom et al.	12/20/1994			
	5,387,579	Meybeck et al.	2/7/1995			
	5,446,070	Mantelle	8/29/1995			
	5,474,891	Murphy	12/12/1995			

|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut for rm 1449/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	10/551,203	\neg
1	Filing Date	June 29, 2006	_
STATEMENT BY APPLICANT	First named Inventor	Simon West	_
	Group Art Unit	1612	Т
(use as many sheets as necessary)	Examiner name	Snigdha Maewall	
Sheet 2of 9	Attorney Docket Number	024944-9015-US00	_

U.S. Patent Documents U.S. Patent Document Number Name of Patentee or Applicant of Cited Date of Publication of Cited Examiner Initials Document Document 5,474,991 Ogata et al. 12/12/1995 5,554,781 Reierson 9/10/1996 5,570,504 Distefano et al. 11/5/1996 5,583,105 Kovacs et al. 12/10/1996 5,589,504 Dannenberg et al. 12/31/1996 5,603,949 Meybeck et al. 2/18/1997 5,607,921 Bernard et al. 3/4/1997 5,643,597 Meybeck et al. 7/1/1997 5,741,518 Ribier et al. 4/21/1998 5,759,526 Simonnet et al. 6/2/1998 5,776,915 Peterson et al. 7/7/1998 5,780,504 **Ptchelintsev** 7/14/1998 5,804,168 Murad 9/8/1998 5,804,216 Terren et al. 9/8/1998 5,807,542 Challis et al. 9/15/1998 5,807,845 Ogata et al. 9/15/1998 5,885,595 Corey et al. 3/23/1999 5,906,811 Hersh 5/25/1999 5,908,846 Bundgaard et al. 6/1/1999 5,916,915 Hong Jong Eon et al. 6/29/1999 5,928,631 Lucas et al. 7/27/1999 5,965,750 Oonishi et al. 10/12/1999

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

for form 1449/PTO

(use as many sheets as necessary)
Sheet 3 of 9

		U.S. Patent Documents	
Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
	5,981,474	Manning et al.	11/9/1999
	6,022,867	Ito et al.	2/8/2000
	6,046,181	Oonishi et al.	4/4/2000
	6,048,891	Wechter	4/11/2000
	6,096,326	Wikholm	8/1/2000
	6,121,249	Weissman et al.	9/19/2000
	6,184,247	Schneider	2/6/2001
	6,403,811	West	6/11/2002
	6,417,223	Sanders et al.	7/9/2002
	6,423,742	Larson	7/23/2002
	6,444,220	Wiley	9/3/2002
	6,479,540	Constantinides et al.	11/12/2002
	6,579,995	West	6/17/2003
	6,599,933	Takada et al.	7/29/2003
	6,645,998	Sanders et al.	11/11/2003
	6,703,384	Sanders et al.	3/9/2004
	6,770,672	Sanders et al.	8/3/2004
	7,179,486	Mulye	2/20/2007
	2002/0131994	Schur et al.	9/19/2002
	2002/0151467	Leung	10/17/2002
	2003/0035812	Ito et al.	2/20/2003
	2003/0206972	Babish et al.	11/6/2003

U.S. Patent Documents

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

Complete if Known

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

THE PHANCE

orm 1449/PTO

 Application Number
 10/551,203

 Filing Date
 June 29, 2006

 First named Inventor
 Simon West

 Group Art Unit
 1612

 Examiner name
 Snigdha Maewall

 Attorney Docket Number
 024944-9015-US00

(use as many sheets as necessary)
Sheet 4 of 9

	U.S. Patent Documents				
Examiner Initials	U.S. Patent Document Number	U.S. Patent Document Number Name of Patentee or Applicant of Cited Document			
	2004/0052754	West et al.	3/18/2004		
	2004/0096493	West	5/20/2004		
	2004/0097431	Sanders et al.	5/20/2004		
	2004/0097472	West et al.	5/20/2004		
	2004/0204343	Fishman	10/14/2004		
	2004/0235938	Sanders et al.	11/25/2004		
	2004/0241225	. West	12/2/2004		
	2005/0009787	West et al.	1/13/2005		
	2005/0089495	West	4/28/2005		
	2006/0241085	West et al.	10/26/2006		
	2006/0257459	West et al.	11/16/2006		
	2006/0281715	West	12/14/2006		
	2007/0042999	West et al.	2/22/2007		
	2007/0135390 .	West et al.	6/14/2007		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract		
	CA	1337992	Shiseido Co. Ltd. et al.	1/23/1996		х		
	EP	0171009	Henkel Corporation	2/12/1986		Х		
	EP	0324387	Takeda Chemical Industries Ltd.	7/19/1989		х		
	EP	0338429	BASF AG	10/25/1989				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

Fatein and Trademark Office. U.S. DEFARTMENT OF COMMERCE properties the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Supplied

form 1449/PTO

 Complete if Known

 Application Number
 10/551,203

 Filing Date
 June 29, 2006

 First named Inventor
 Simon West

 Group Art Unit
 1612

 Examiner name
 Snigdha Maewall

 Attorney Docket Number
 024944-9015-US00

(use as many sheets as necessary)
Sheet 5 of 9

U.S. Patent Documents

			FOREIGN PATENT DOCUME	NTS		
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	EP	0430045	Senju Pharmaceutical Co., Inc.	6/5/1991		Х
	EP	0430336	Zambon Group SpA	6/5/1991		х
	EP	0436911	Eisai Co., Ltd.	7/17/1991		X
	EP	0565007	Senju Pharmaceutical Co., Inc.	10/13/1993		Х
	EP	0574255	Indena SpA	12/15/1993		х
	EP	0617963	Senju Pharmaceutical Co., Inc.	10/5/1994		х
	EP ·	0641790	Scotia Holdings Plc	3/8/1995		х
	EP	0661053	Senju Pharmaceutical Co., Inc.	7/5/1995		х
	EP	0679399	Senju Pharmaceutical Co., Inc.	11/2/1995		х
	EP .	0680760	Senju Pharmaceutical Co., Inc.	11/8/1995		х
	EP	0684043	Senju Pharmaceutical Co., Inc.	12/29/1995		х
	EP	0699440	Senju Pharmaceutical Co., Inc.	3/6/1996		х
	EP	0826365	Senju Pharmaceutical Co., Inc.	3/4/1998		Х
	EP	0845216	Showa Denko Kabushiki Kaisha	6/3/1998		Х
	EP	0965328	Kao Corporation	12/22/1999		х
	EP	1023897	Showa Denko KK	8/2/2000		х
	EP	1053749	Senju Pharmaceutical Co., Inc.	11/22/2000		Х
	GB	1121683	General Aniline & Film Corporation	7/31/1968		Х
	ĢB	2227662	E.R. Squibb & Sons Inc.	8/8/1990		, X
	JР	53015381	Eisai Co. Ltd.	2/13/1978		Х
	JP	. 58180410	Shiseido Co. Ltd. et al.	10/21/1983		X
	JР	59044375	Senju Seiyaku KK	3/12/1984		Х

	· · · ·	
Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

Л

JP

JР

11199465

2001247585

2002080475

(use as many sheets as necessary)
Sheet 6of 9

Complete if Known					
Application Number	10/551,203				
Filing Date	June 29, 2006				
First named Inventor	Simon West				
Group Art Unit	1612				
Examiner name	Snigdha Maewall				
Attorney Docket Number	024944-9015-US00				

7/27/1999

9/11/2001

3/19/2002

X

X

X

X

U.S. Patent Documents FOREIGN PATENT DOCUMENTS

Country Foreign Patent Document Name of Patentee or Date of Publication of Cited English Examiner Translation Initials Code Number Applicant of Cited Document Document Abstract JР 59157091 Sanyo Chem. Ind. Ltd. 9/6/1984 X ЛР 61086940 **Kao Corporation** 5/2/1986 X Л 61091137 5/9/1986 X Kao Corporation JP 61233631 **Kao Corporation** 10/17/1986 Х JР 62195393 Yakult Honsha KK 8/28/1987 X ЛР 63139972 Senju Pharmaceutical Co., Inc. X 6/11/1988 JP X 4208209 Showa Denko KK 7/29/1992 IP 5132700 Sunstar Chemical Industries 5/28/1993 Х Љ 6048962 Morimoto Kazutoshi 2/22/1994 \mathbf{X} X JP 6078214 Senju Pharmaceutical Co., Inc. 10/5/1994 JP 7011291 **Kao Corporation** 1/13/1995 X JP 7278587 10/24/1995 X **Kao Corporation** JP Х 7316170 **Kao Corporation** 12/5/1995 ЛР 8193089 7/30/1996 Х **Kao Corporation** JР 8311085 X **Kao Corporation** 11/26/1996 ЛР 9044375 Hitachi Ltd. 2/14/1997 X Л 9309813 Nonogawa Shoji KK 12/2/1997 X ЛР 10045783 Showa Denko KK 2/17/1998 \mathbf{X} JP 11043436 Showa Denko KK 2/16/1999 X JР 11199424 7/27/1999 Nonogawa Shoji KK X

	· · · · · · · · · · · · · · · · · · ·	,	
Examiner		Date	
Signature		Considered	

Nonogawa Shoji KK

Nippon Oils & Fats Co. Ltd.

Takada Jiro

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

rm 1449/PTO

Application Number 10/551,203

Filing Date June 29, 2006

First named Inventor Simon West

Group Art Unit 1612

Examiner name Snigdha Maewall

Attorney Docket Number 024944-9015-US00

Complete if Known

(use as many sheets as necessary)
Sheet 7of 9

U.S. Patent Documents

]	FOREIGN PATENT DOCUME	NTS		
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	SU	925961	MO I T Pishchevoj Promy	5/7/1982		Х
	wo	91/17987	SmithKline & French Laboratories Ltd.	11/28/1991		Х
	wo	92/03122	CEVC	3/5/1992		Х
	wo	92/07544	Senju Pharmaceutical Co., Inc.	5/14/1992		Х
	wo	92/08459	Kabi Pharmacia AB	5/29/1992		Х
	wo	93/02661	LVMH Rech	2/18/1993		Х
	wo	93/15731	Lamb	8/19/1993		· X
	wo	93/24131	Procter & Gamble Pharmaceuticals Inc.	12/9/1993		х
	wo	95/31217	A/S Dumex	11/23/1995		Х
	wo	95/34303	Arcturus Pharmaceutical Corp.	. 12/21/1995		Х
	wo	96/17852	Kao Corporation	6/13/1996		Х
	wo	96/20715	Perstorp AB	7/11/1996		Х
	wo	96/21440	Alpha-Therapeutics Inc. et al.	7/18/1996		Х
	wo	96/29336	Medical Research Council et al.	9/26/1996		Х
	wo	97/14705	Showa Denko KK	4/24/1997		Х
	wo	97/35591	Inspire Pharmaceuticals Inc.	10/2/1997		Х
	wo	99/58555	Vyrex Corporation	11/18/1999		Х
	wo	00/08033	The University of Kansas	2/17/2000		Х
	wo	00/16772	Research Development Foundation	3/30/2000		х
	wo	00/30620	Gasco	6/2/2000		Х
	wo	00/43380	Swig Pty. Ltd.	7/27/2000		х

Examiner Signature	Date Considered	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

r form 1449/PTO

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

> (use as many sheets as necessary) Sheet 8of 9

Complete if Known				
Application Number	10/551,203			
Filing Date	June 29, 2006			
First named Inventor	Simon West			
Group Art Unit	1612			
Examiner name	Snigdha Maewall			
Attorney Docket Number	024944-9015-US00			

U.S. Patent Documents

FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	wo	00/57876	Lipogenics, Inc.	10/5/2000		Х
	wo	00/59475	Lipocine Inc.	10/12/2000		Х
-	wo	00/69865	Swig Pty. Ltd.	11/23/2000		Х
	wo	00/71094	Amway Corporation	11/30/2000		Х
	wo	00/71125	LTS Lohmann Therapie- Systeme AG	11/30/2000		х
	wo	01/19372	Pharmacia & Up John SpA	3/22/2001	,	х
	wo	01/22937	Sonus Pharmaceuticals, Inc.	4/5/2001		X
	wo	01/35998	Pharmaderm Laboratories, Ltd.	5/25/2001		Х
	wo	01/46204	Merck Frosst Canada & Co.	6/28/2001		Х
	wo	01/58889	Research Development Foundation	8/16/2001		Х
	wo	02/13810	Vyrex Corporation	2/21/2002		X
	wo	02/26238	Tocovite Pty Ltd.	4/4/2002		Х
	wo	02/36736	The Regents of University of California	5/10/2002		х
	wo	02/39996	Pharmacia & Up John Company	5/23/2002		х
	wo	03/011303	Vital Health Sciences Pty. Ltd.	2/13/2003		Х
	wo	03/039461	Research Development Foundation	5/15/2003		х
	wo	03/043570	Galieo Laboratories Inc.	5/30/2003		х
	wo	03/049774	Vital Health Sciences Pty. Ltd.	6/19/2003		X
	wo	03/053407	Research Development Foundation	7/3/2003		х
	wo	03/101480	Perricone	12/11/2003		Х

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

or form 1449/PTO

Complete if Known

Application Number 10/551,203

Filing Date June 29, 2006

First named Inventor Simon West

Group Art Unit 1612

Examiner name Snigdha Maewall

Attorney Docket Number 024944-9015-US00

(use as many sheets as necessary)
Sheet 9of 9

U.S. Patent Documents

FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	wo	2004/060315	Perricone	7/22/2004	-	Х
	wo	2004/064831	Vital Health Sciences Pty. Ltd.	8/5/2004		Х
	wo	2004/092186	Vital Health Sciences Pty. Ltd.	10/28/2004		х
	wo	2004/092187	Vital Health Sciences Pty Ltd.	10/28/2004		X.
	wo	2005/023282	LTT Bio-Pharma Co. Ltd.	3/17/2005		Х
	wo	2005/084678	Vital Health Sciences Pty. Ltd.	9/15/2005		Х
	wo	2006/012692	Vital Health Sciences Pty. Ltd.	2/9/2006		х
	wo	2006/092024	Vital Health Sciences Pty. Ltd.	9/8/2006		Х
	wo	2006/092025	Vital Health Sciences Pty. Ltd.	9/8/2006		х
	wo	2006/133506	Vital Health Sciences Pty. Ltd.	12/21/2006		Х
	wo	2007/070981	Vital Health Sciences Pty. Ltd.	6/28/2007		X

Examiner	·	Date
Signature		Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Complete if Known for form 1449B/PTO Application Number 10/551,203 INFORMATION DISCLOSURE Filing Date June 29, 2006 First Named Inventor Simon West STATEMENT BY APPLICANT Group Art Unit 1612 (use as many sheets as necessary) Examiner Name Snigdha Maewall Sheet 6 Attorney Docket Number 024944-9015-US00

DEC 1 5 2008

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	ABERG, F. et al., "Distribution and redox state of ubiquinones in rat and human tissues," Arch. Biochem. Biophys. (1992) 295(2):230-234
	ALMEIDA, M.E.M. et al., "Evaluation of soybean oil deodorization distillate for Vitamin E recovery," Arq. Biol. Tecnol. (1994) 37(4):1003-1011
	BARRETT, C.W. et al., "The effect of particle size and vehicle on the percutaneous absorption of fluocinolone acetonide," Brit. J. Dermatol. (1965) 77:576-578
	BIKERMAN, J.J., "Mechanical destruction of young and old foam films," J. Phys. Chem. (1952) 56:164-165
	BLOM, J.H. et al., "Reproductive success of female rainbow trout (Oncorhynchus mykiss) in response to graded dietary ascorbyl monophosphate levels," Biol. of Reproduction (1995) 52:1073-1080
	CEVC, G. "Transdermal drug delivery of insulin with ultradeformable carriers," Clin. Pharmacokinet. (2003) 42(5):461-474
	CEVC, G. et al., "Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin," Biochim. Biophys. Acta (1998) 1368:201-215
	DE WOLFE, F.A. et al., "Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands," Pharmacol. Rev. (2000) 52(2):207-236
	DEVARAJ, S. et al., "Modulation of monocyte-macrophage function with alpha-tocopherol: implications for atherosclerosis," Nat. Rev. (2002) 60(1):8-14

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

NFORMATION DISC	CLOSURE
STATEMENT BY AP	PLICANT

for form 1449B/PTO

Complete if Known Application Number 10/551,203

INFORMATION DISCLOSURE STATEMENT BY APPLICANT			OSURE	Filing Date	June 29, 2006	
			LICANT	First Named Inventor	Simon West	
				Group Art Unit	1612	
(use as many sheets as necessary)			y)	Examiner Name	Snigdha Maewall	
Sheet	2	of	6	Attorney Docket Number	024944-9015-US00	

zine, journal, serial,
monocyte 000) 29(8):790-792
Biochim. Biophys.
pages (downloaded
n C," J. Nutrition
ions," Proc. Natl.
ar. Syst. (2003)
rent knowledge ardiol. (2007)
f CD36 at the level
Orug Del. (2000)

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

6

 Complete if Known

 Application Number
 10/551,203

 Filing Date
 June 29, 2006

 First Named Inventor
 Simon West

 Group Art Unit
 1612

 Examiner Name
 Snigdha Maewall

 Attorney Docket Number
 024944-9015-US00

(use as many sheets as necessary)

Sheet 3 of

for form 1449B/PTO

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.			
	HERON-MILHAVET, L. et al., "Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice," Endocrinology (2004) 145:4667-4676			
	KAGAN, V. et al., "Antioxidant effects of ubiquinones in microsomes and mitochondria are mediated by tocopherol recycling," Biochem. Biophys. Res. Commun. (1990) 169(3):851-857			
	KARRER, V.P. et al., "d,l-alpha-tocopherol-phosphorsaure-ester," Zurich, Chemisches Institut der Universitat (1933) p. 1137-1138, in German			
	KING, M.J. et al., "Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats," Diab. Tech. Therap. (2002) 4(4):479-488			
	KNOWLER, W.C. et al., "Preventing Non-insulin-dependent diabetes," Diabetes (1995) 44:483-488			
	LANGSJOEN, P.H. et al., "Overview of the use of CoQ10 in cardiovascular diseases," Biofactors (1999) 9:273-284			
	LASS, A. et al., "Electron transport-linked ubiquinone-dependent recycling of α-tocopherol inhibits autooxidation of mitochondrial membranes," Arch. Biochem. Biophys. (1998) 352(2):229-236			
·	LEE, C-F. et al., "Attenuation of UV-induced apoptosis by coenzyme Q10 in human cells harboring large-scale deltion of mitochontrial DNA," Ann. N.Y. Acad. Sci. (2005) 1042:429-438			
	LEI, B. et al.,. "Progress in alpha-tocopherol preparation technology, Xiandai Huagong (1997) 17(7):13-15			

Examiner		Date	
Signature	·	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number. Complete if Known or form 1449B/PTO Application Number 10/551,203 INFORMATION DISCLOSURE Filing Date June 29, 2006 STATEMENT BY APPLICANT First Named Inventor Simon West Group Art Unit 1612 (use as many sheets as necessary) **Examiner Name** Snigdha Maewall Sheet Attorney Docket Number 024944-9015-US00

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	MAGUIRE, J.J. et al., "Succinate-ubiquinone reductase linked recycling of alpha-tocopherol in reconstituted systems and mitochondria: requirement for reduced ubiquinone," Arch. Biochem. Biophys. (1992) 292(1):47-53
	MELLORS, A. et al., "The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol," J. Biol. Chem. (1966) 241(19):4353-4356
	MERCK INDEX, THE, "α-estradiol" Thirteenth Edition, Whitehouse Station, NJ (2001) page 660
	MERCK INDEX, THE, "Fludarabine to Fludeoxyglucose F18" pages, Thirteenth Edition, Whitehouse Station, NJ (2001) pages 729-730
	MIYAMOTO, S. et al., "Synthesis of a novel phosphate ester of a vitamin E derivative and its antioxidative activity," Biosci. Biotech. Biochem. (1998) 62(12):2463-2466
	MORGAN, T.M. et al., "Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol," J. Pharm. Sci. (1998) 87(10):1226-1228
	MORGAN, T.M. et al., "Enhanced transdermal delivery of sex hormones in swine with a novel topical aerosol," J. Pharm. Sci. (1998) 87(10):1219-1225
	MORTENSEN, S.A., "Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone)," Clin. Investig. (1993) 71(Suppl.8):S116-S123
	MUNTEANU, A. et al., "Modulation of cell proliferation and gene expression by alpha-tocopheryl phosphates: relevance to atherosclerosis and inflammation," Biochem. Biophys. Res. Comm. (2004) 318(1):311-316

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number. Complete if Known form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet

Application Number	10/551,203		
Filing Date	June 29, 2006		
First Named Inventor	Simon West		
Group Art Unit	1612		
Examiner Name	Snigdha Maewall		
Attorney Docket Number	024044 0015 11000		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.		
	OSTRENGA, J. et al., "Significance of vehicle composition I: Relationship between topical vehicle composition, skin penetrability, and clinical efficacy," J. Pharm. Sci. (1971) 60(8):1175-1179		
	OWENS, D.R. et al., "Alternative routes of insulin delivery," Diabet. Med. (2003) 20:886-898		
	PARKER et al., "Neonatal vitamin K administration and childhood cancer in the North of England: retrospective case-control study," BMJ (1998) 316:189-193		
	POTTS, R.O. et al., "Predicting skin permeability," Pharm. Res. (1992) 9(5):663-669		
	PURATCHIKODY, A. et al., "Reverse phase - high performance liquid chromatographic determination of atorvastatin calcium in solid dosage forms," Pharma. Review (2003) 1(2):79-80, 83 - STN File CA, Abstract 139:399976 only		
	SEVAST'IANOV, V.I. et al., "Transdermal delivery of insulin," Meditsinskaia Tekhnika (2003) 2:21-24		
	SEYAMA, Y. et al., "Comparative effects of Vitamin K2 and estradiol on experiemental arteriosclerosis with diabetes mellitus," Int. J. Vitam. Nutr. Res. (2000) 70(6):301-304, Abstract only		
	SINGH, R.B. et al., "Randomized double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction," Cardiov. Drugs Ther. (1998) 12:347-353		
	Stedman's Medical Dictionary, "Tocopherol," "Tocotrienol," and "Vitamin K1", 22nd Edition, Williams & Wilkins Co. (1972) p. 1303 and 1400		

Examiner	Dat	e
Signature	Con	nsidered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Complete if Known e for form 1449B/PTO Application Number 10/551,203 INFORMATION DISCLOSURE Filing Date June 29, 2006 First Named Inventor STATEMENT BY APPLICANT Simon West Group Art Unit 1612 (use as many sheets as necessary) Examiner Name Snigdha Maewall Sheet Attorney Docket Number 024944-9015-US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, s symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.				
	YOUNIS et al., "The prevention of type 2 diabetes mellitus: recent advances," Q.J. Med. (2004) 97:451-455			

Examiner	Date	
Signature	 Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.